AZNAstraZenecaFinished
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
Advanced Solid Tumours
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 54 (final count)
- Started
- Dec 1, 2020
- Main results expected
- Feb 18, 2025
- Fully finished
- Feb 18, 2025
- Results posted
- Jun 25, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort A (aST): Objective Response Rate (ORR).
Measured over: 2 years 4 months
Cohort B (mCRPC): Composite Response Rate.
Measured over: Up to 2 years 4 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04564027 · record last updated 2025-08-29 · checked 2026-11-09 15:47 UTC